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T cell activation is tightly regulated to avoid autoim-
munity. Gene related to anergy in lymphocytes
(GRAIL, encoded by Rnf128) is an E3 ubiquitin ligase
associated with T cell tolerance. Here, we generated
and analyzed GRAIL-deficient mice and found they
were resistant to immune tolerance induction and
exhibited greater susceptibility to autoimmune
diseases than wild-type mice. GRAIL-deficient naive
T cells, after activation, exhibited increased prolifera-
tion and cytokine expression than controls and did
not depend on costimulation for effector generation.
Moreover, GRAIL-deficient regulatory T (Treg) cells
displayed reduced suppressive function, associated
with increased Th17 cell-related gene expression.
GRAIL-deficient naive and Treg cells were less effi-
cient in downregulating T cell receptor (TCR)-CD3
expression after activation and exhibited increased
NFATc1 transcription factor expression; GRAIL
expression promoted CD3 ubiquitinylation. Our
results indicate that GRAIL, by mediating TCR-CD3
degradation, regulates naive T cell tolerance induc-
tion and Treg cell function.
INTRODUCTION
T cell activation is tightly regulated to ensure effective elimination
of invading pathogens as well as maintaining tolerance against
self-tissues. T cells are regulated by extracellular signals, espe-
cially the positive and negative costimulatory molecules on
antigen-presenting cells (APCs), and also by delicate intracellular
signal transducers and regulators. E3 ubiquitin ligases, including
cbl-b and Itch, have been shown to play important roles in regu-
lation of T cell tolerance (Heissmeyer and Rao, 2004; Liu et al.,
2005). GRAIL is a type I transmembrane protein localized to
endosomal compartment with homology to RING finger proteins
whose expression was previously associated with T cell anergy
induction (Anandasabapathy et al., 2003; Heissmeyer et al.,670 Immunity 32, 670–680, May 28, 2010 ª2010 Elsevier Inc.2004; Seroogy et al., 2004). The GRAIL mRNAwas initially deter-
mined to be induced in anergic T helper 1 (Th1) cells (Anandasa-
bapathy et al., 2003). Previously, we reported that T cells
activated in the absence of both CD28 and ICOS costimulation
developed into tolerant T cells, associatedwithmarkedly upregu-
latedGRAIL expression (Nurieva et al., 2006). Consistent with the
notion that GRAIL regulates T cell anergy, overexpression of
GRAIL in T cell hybridomas or in primary cells reduced T cell
cytokine expression (Anandasabapathy et al., 2003). Moreover,
expression of an enzymatic inactive form of GRAIL in primary
T cells prevented T cell anergy (Seroogy et al., 2004). In addition
to anergic CD4+ T cells, enhanced amount of GRAIL was de-
tected in regulatory T (Treg) cells, and overexpression of GRAIL
in Ova-specific CD4+ T cell line was reported to convert these
cells to a regulatory phenotype in the absence of detectable
Foxp3 expression (MacKenzie et al., 2007). Despite the above
interesting preliminary data on GRAIL expression and function,
the physiological function of GRAIL in immune regulation is not
well understood, in part because of lack of genetic studies.
In the current study, we generated and analyzedmice deficient
in Rnf128 (encoding GRAIL). GRAIL-deficient mice exhibited
impairments in peripheral tolerance induction and greater
susceptibility to autoimmune diseases. Naive T cells lacking
GRAIL showed greatly enhanced proliferation and cytokine
production after T cell receptor (TCR) activation and did not
depend on CD28 and ICOS for their effector cytokine expres-
sion. We also found that lack of GRAIL abrogated suppressive
function of Treg cells in an interleukin-21 (IL-21)-dependent
manner. Both naive and Treg cells from GRAIL-deficient mice
were less efficient in downregulation of their TCR-CD3 expres-
sion and exhibited increased NFATc1 transcription factor
expression after TCR activation. Moreover, GRAIL promotes
CD3 ubiquitinylation. Our results thus indicate GRAIL as an
essential regulator of T cell tolerance by regulating naive T cell
tolerance and Treg cell function.
RESULTS
Generation of GRAIL-Deficient Mice
In order to understand the physiological function of GRAIL, we
generated mice deficient in Rnf128 by replacing part of exon 4
Figure 1. GRAIL Is Required for T Cell Tolerance Induction In Vivo
(A) WT and Rnf128/ mice were fed five times with OVA or PBS. Seven days
after the last feeding, all mice were immunized with OVA in CFA. Seven days
later, mice were sacrificed and analyzed. Spleen cells from these mice were
stimulated with the indicated concentration of Ova. Proliferation was assayed
after 3 days of treatment by adding [3H]-thymidine to the culture for the last
8 hr. IL-2 was measured 1 day later, and effector cytokines (IFN-g and IL-4)
were measured after 4 days of treatment. Each experimental group consisted
of three mice. The graph shows means ± standard deviation (SD). Data are
a representative of two individual experiments.
(B) WT and Rnf128/ OT-II TcR transgenic mice (three mice per group) were
injected twice with 500 mg of soluble Ova peptide to induce T cell tolerance or
with PBS as control. Seven days after the second administration of the
peptide, flow cytometry-sorted Va2+CD44+CD4+ T cells were isolated from
spleen and restimulated with different concentrations of plate-bound anti-
CD3. Proliferation, IL-2 production, and secretion of IFN-g were assessed as
in (A). The graph showsmeans ± standard deviation (SD). Data are a represen-
tative of two individual experiments with consistent results.
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GRAIL Regulates T Cell Activation and Functionand all of exons 5 and 6 with the neomycin-resistant gene, which
removes amino acids 283–385 encompassing most of the RING
domain (amino acids 277–317) (Figure S1A). Rnf128 gene target-
ing was confirmed by Southern blot and PCR analysis of
genomic DNA from several embryonic stem cell clones (Fig-
ures S1B and S1C). The targeted ESCs were used to generate
GRAIL-deficient mice. RT-PCR analysis of Rnf128 expression
in various tissues revealed that the appropriate regions of
Rnf128 were deleted (Figure S1D).
GRAIL-deficient male and female mice were viable, fertile, and
grossly normal. Analysis of spleen and thymus of 6- to 8-week-
old mice indicated a normal ratio of CD4+ and CD8+ T cells
(Figure S1E). In addition, CD4+ and CD8+ T cells from spleen of
GRAIL-deficient mice at this age did not show altered expression
of activation markers CD69, CD44, and CD25 and naive T cells
marker CD62L (Figure S1G). Furthermore, GRAIL-deficient
mice displayed the same percentages of Treg cells in spleen
and thymus aswild-typemice (Figure S1F). Thus, T cells in young
GRAIL-deficient mice appear to develop normally.
GRAIL Is Required in Immune Tolerance Induction
In Vivo
Next, we examined the role of GRAIL in oral tolerance, a form of
peripheral tolerance. Wild-type (WT) and Rnf128/ mice were
given daily doses of 2 mg of ovalbulim (Ova) protein intragastri-
cally for a total of five times, after subcutaneous immunization
with Ova protein emulsified in complete Freud’s adjuvant (CFA).
Seven days after immunization, splenocytes were restimulated
with different concentrations of Ova protein, and proliferation
and cytokine production were examined. Whereas WT T cells
from the Ova-fed group exhibitedmarkedly reduced proliferation
and IL-2, IFN-g, and IL-4 production upon Ova protein restimu-
lation, proliferation and cytokine production by GRAIL-deficient
T cells from Ova- and PBS-fed mice were indistinguishable
(Figure 1A).
To further ascertain the role of GRAIL in induction of CD4+
T cell tolerance, Rnf128/ mice were bred with OT-II TCR
transgenic mice, and both WT and Rnf128/ OT-II TCR trans-
genic mice were injected twice with a high dose of soluble Ova
peptide to induce T cell tolerance or with PBS as control. Seven
days after the second administration of the peptide, clonotypic
CD4+ T cells were isolated from spleen and restimulated with
different concentrations of plate-bound anti-CD3. Although WT
T cells from Ova-sensitized mice showed decreased prolifera-
tion, accompanied with markedly reduced IL-2 and IFN-g
production, Rnf128/T cells from Ova- or PBS-treated mice
were identical in their responses (Figure 1B). These data indi-
cated that GRAIL controls the induction of antigen-specific
CD4+ T cell tolerance.
Rnf128/ Mice Exhibit Increased Susceptibility
to Autoimmune Diseases
Because GRAIL plays a critical role in regulating T cell tolerance
in experimental models, we further investigated if deficiency of
GRAIL leads to spontaneous autoimmunity in aged mice.
Rnf128/mice on C57BL/6 3 129 background at age of 2,
18–20, and 26–28 months, together with age- and sex-matched
wild-type mice (Figures 2A and 2B) and Rnf128/ mice on
C57BL/6 background at age 18–20 months (Figures 2C and 2D),Immunity 32, 670–680, May 28, 2010 ª2010 Elsevier Inc. 671
Figure 2. GRAIL Deficiency Leads to Autoimmune Symptoms
(A) Percentages of WT and Rnf128/ (/) mice on C57BL/6 3 129 back-
ground at 2 (n = 8 [WT], n = 8 [/]), 18–20 (n = 7 [WT], n = 10 [/]) or
26–28 (n = 6 [WT], n = 4 [/]) months of age with enlarged sizes of spleen
and mLN. (A and C) Sera were collected from WT and Rnf128/ (/) mice
on C57BL/6 3 129 background (A) or from 18–20 months old WT and
Rnf128/ mice on C57BL/6 background (n = 5 [WT], n = 5 [/]) and anti-
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672 Immunity 32, 670–680, May 28, 2010 ª2010 Elsevier Inc.were examined. Rnf128/ and WT mice had similar sizes of
spleens and mesenteric lymph nodes at 2 months of age. How-
ever, at 18–20 or 26–28 months of age, 27 to 50 percent, respec-
tively, of Rnf128/ mice exhibited splenomegaly and 27 to
75 percent, respectively, increased sizes of mesenteric lymph
nodes (Figure 2A), but not other lymph nodes (data not shown).
Histological analysis showed massive infiltration of lymphocytes
in the lungs of all GRAIL-deficient mice at 18–20 months of age
(Figures S2A and S2B). Moreover, kidneys in these mice were
infiltrated by mononuclear cells as well, although variable in
severity but consistently present in all GRAIL-deficient mice
(Figures S2D and S2E). In addition, minor infiltration could be
detected in the liver of Rnf128/ mice (Figures S2G and S2H),
but other organs examined were free of infiltration. In WT
littermates, no infiltration could be detected in any organ. In
addition, Rnf128/mice developed higher titers of dsDNA anti-
bodies in their sera starting at 18–20 months when compared
with WT mice (Figures 2A and 2C). Splenic CD4+ T cells from
aged Rnf128/mice also showed significantly enhanced levels
of proinflammatory cytokine IFN-g and IL-17 expression (Figures
2B and 2D and Figures S2J and S2K).
The above results suggest a critical role of GRAIL in preventing
lymphoproliferative and autoimmune responses. To further
examine the role of GRAIL in autoimmune diseases, we immu-
nized female Rnf128+/+, Rnf128+/, Rnf128/ mice on C57BL/
6 3 129 mixed background with MOG peptide emulsified with
CFA to induce experimental autoimmune encephalomyelitis
(EAE). WT mice developed very mild disease because of their
partial 129 genetic background (Figure 3A). In contrast,
Rnf128/ mice showed markedly higher scores of EAE. Inter-
estingly, Rnf128+/ mice with mixture of T cells containing WT
or Rnf128/ allele of GRAIL due to X chromosome inactivation
also developed marked symptoms of EAE. Consistent with
development of EAE symptoms, Rnf128/ mice accumulated
more CD4+ T cells in the central nervous system (CNS) (Fig-
ure 3B). We further analyzed the cytokine production profiles
by CD4+ cells infiltrating into the CNS and in spleen. CNS-infil-
trating and splenic CD4+ T cells from Rnf128+/ and Rnf128/
mice produced increased amounts of IL-17 and IFN-g (Figure 3B
and Figure S3A). In addition, splenic cells from Rnf128/ mice
exhibited increased proliferation in response to MOG restimula-
tion (Figure S3A). Our results indicate a critical role of GRAIL in
controlling autoimmune responses by negatively regulating
autoreactive T cell proliferation and IFN-g and IL-17 expression.
To determine whether expression of GRAIL in T cells is critical
for controlling EAE, we adoptively transfer CD4+ T cells fromWT
or Rnf128/ mice on B6 background into Rag1/ mice. Upon
immunization with MOG, recipient mice containing Rnf128/
T cells developed EAE 6 days earlier compared to recipients of
WT cells (Figure 3C). Moreover, the clinical scores of EAE were
higher in mice with Rnf128/ T cells than in those with WT cells.dsDNA IgG was measured by ELISA. The graph shows means ± SD. p values
were calculated with the t test by comparison of the concentration of ds-DNA
in sera WT and Rnf128/mice. (B and D) Splenocytes from 18–20 month old
WT orRnf128/mice on 1293B6 background (B) and onB6background (D)
were assessed for IL-17 and IFN-g using intracellular cytokine staining.
p values were calculated with the t test by comparison of the percentage of
CD4+IFN-g+ or CD4+IL-17+ T cells between WT and Rnf128/ mice.
Figure 3. Rnf128/ Mice Exhibit Exacer-
bated EAE
(A and B) WT, Rnf128+/, Rnf128/ mice were
immunized with MOG peptide to induce EAE.
The result (means ± SD) shown is a representative
of two independent experiments with similar
results [n = 8 (WT), n = 7 (+/), n = 11 (/)].
(C and D) CD4+ T cells from WT and Rnf128/
mice were i.v. transferred into Rag1/ mice. The
recipient mice were induced EAE, disease
incidence and score were measured daily, and
means ± SD of all mice in each group were shown
[n = 11 (WT), n = 11 (/)]. Data represent two
independent experiments with consistent results.
(B and D) Mononuclear cells isolated from spinal
cords and brains of experimental mice were
stained with anti-CD4 and CD11b and analyzed
by flow cytometry. Mononuclear cells from CNS
were stimulated for 5 hr with PMA and ionomycine,
and spleenocytes were restimulated with MOG
peptide for 24 hr, followed by intracellular staining
of IL-17 and IFN-g, and analyzed in CD4+ gate.
Numbers in dot plot quadrants represent the
percentages.
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was higher in Rnf128/ than WT CD4+ T cell populations (Fig-
ure 3D and Figure S3B). Further examination of MOG-reactive
T cells revealed the enhanced proliferation by Rnf128/
T cells when compared to WT cells, suggesting an intrinsic role
of GRAIL in CD4+ T cells in controlling autoimmune responses.
Rnf128/ T Cells Are Hyper-responsive
to TCR Stimulation
To understand GRAIL function in T cells, we first re-examined
Rnf128 expression. Flow cytometry-sorted CD62LhiCD44lo
CD25 naive CD4+ T cells were activated with plate-bound
anti-CD3 or anti-CD3 and anti-CD28 for 1, 2, or 3 days, and
GRAIL mRNA expression was analyzed by real-time RT-PCR.
GRAIL mRNA expression was detected on day 0, which was
upregulated on day 2 after anti-CD3 stimulation and further
increased on day 3, whereas costimulation with anti-CD28
potentiated GRAIL expression on day 2, which was downregu-
lated on day 3 (Figure S4A). Because T cells activated under
these conditions were not tolerant, our results suggest that
GRAIL may be involved in normal naive T cell activation.
To further determine the role of GRAIL during T cell activation,
flow cytometry-sorted naive CD4+ T cells from Rnf128+/+and
Rnf128/ mice on B6 background were activated with plate-
bound anti-CD3 alone or together with anti-CD28. Rnf128/
CD4+ T cells exhibited greatly enhanced proliferation and cyto-
kine (IL-2 and IFN-g) production when compared to WT cells
in response to anti-CD3 stimulation (Figure 4A). Addition of
anti-CD28 enhanced T cell proliferation and cytokine production
in WT and Rnf128/ T cells. Thus, these data indicate that
GRAIL negatively regulates TCR signaling strength. We also
used Rnf128/ mice bred with OT-II TCR transgenic mice.
Consistent with the above results, Rnf128/ OT-II cells ex-
hibited greater proliferation compared with WT OT-II cells when
activated with OVA peptide and WT APCs (Figure 4B). Moresignificant differences in IL-2 production between WT and
Rnf128/ OT-II cells were observed in the presence of low
concentrations of Ova peptide compared to higher concentra-
tions. Next, we assessed if Rnf128/ CD4+ T cells can be toler-
ized when activated in the absence of costimulatory signals.
Naive CD4+ T cells from OT-II TCR transgenic mice or
Rnf128/ OT-II mice were activated in the presence of OT-II
peptide and irradiated APCs from WT mice or those deficient
in B7.1, B7.2, and B7h (TKO). As we reported before (Nurieva
et al., 2006), naive WT OT-II cells, when activated with TKO
APCs, were impaired in proliferation and IL-2 production, and
exhibited absence of effector cytokine expression in response
to anti-CD3 restimulation (Figure 4B). In contrast, Rnf128/
OT-II T cells activated with TKO APCs expressed these cyto-
kines. Thus, the deficiency in GRAIL leads to T cell hyperactiva-
tion and their independency on costimulation for activation.
To further characterize the role of GRAIL in T cell effector
function, naive CD4+ T cells from WT and Rnf128/ mice were
differentiated in vitro under Th1, Th2, or Th17 cell conditions
for 5 days and analyzed for their cytokine production by intracel-
lular cytokine staining and ELISA. IFN-g and IL-17 expression by
Rnf128/ Th cells activated under Th1 and Th17 cell condition,
respectively, was markedly enhanced compared to WT cells
(Figure 4C). However, under Th2 cell polarizing conditions,
Rnf128/ T cells exhibited decreased percentages of IL-4-
producing cells compared to WT cells, whereas IL-5 production
appeared to be normal (Figure 4C). Thus, GRAIL may negatively
regulate IFN-g and IL-17 expression.
To further analyze T cell responses in vivo,Rnf128/ and their
WT littermate mice on C57BL/6 3 129 mixed background were
immunized with Ova protein emulsified in CFA. Seven days after
immunization, splenocytes were restimulated with Ova peptide,
and cytokine production was examined. T cells from Rnf128/
mice exhibited enhanced proliferation, IL-2 secretion, and
production of Th1 (IFN-g) and Th17 (IL-17, IL-21, and IL-22)Immunity 32, 670–680, May 28, 2010 ª2010 Elsevier Inc. 673
Figure 4. Rnf128/ T Cells Are Hyper-responsive to TCR Signaling
(A) Flow cytometry-sorted naive CD4+ T cells were activated with plate-bound anti-CD3 alone or together with anti-CD28. Proliferation was assayed after 3 days
of treatment by adding [3H]-thymidine to the culture for the last 8 hr. IL-2 wasmeasured 1 day later, and IFN-gweremeasured after 4 days of treatment. The graph
shows means ± standard deviation (SD). The results shown are a representative of at least two independent experiments.
(B) Flow cytometry-sorted naive wild-type or Rnf128/ OT-II cells were activated with Ova peptide and irradiated APCs from WT or B7.1/B7.2/B7h KO (TKO)
mice for 5 days. IL-2 production was determined 24 hr after T cell activation by ELISA. Proliferation was assayed 3 days after treatment by adding [3H]-thymidine
to the culture for the last 8 hr. Five days later, differentiated T cells were restimulated with anti-CD3 for 24 hr, and effector cytokine production was measured by
ELISA. The graph shows means ± standard deviation (SD). p values were calculated with the t test by comparing the IL-2 production by WT and Rnf128/ CD4+
T cells activated with Ova peptide and WT APCs and are indicated as follows: *p < 0.01; **p < 0.001. The results shown are a representative of at least three
independent experiments.
(C) Flow cytometry-sorted naive CD4+ T cells fromWT and Rnf128/mice were polarized under Th1, Th2, and Th17 conditions. Five days later, effector cytokine
production was analyzed by intracellular staining and ELISA. The graph showsmeans ± standard deviation (SD). The results shown are a representative of at least
two independent experiments.
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IL-13) were decreased in Rnf128/ mice, which might have
been caused by increased IFN-g expression in vivo (Figure S4B).
These results indicate that GRAIL negatively regulates T cell
activation and Th1-Th17 effector function in vitro and in vivo.
We also investigated the role of GRAIL in an asthma model
induced by an exogenous antigen. WT or Rnf128/ mice were
intraperitoneally sensitized twice with Ova protein in alum with
2 week intervals. Ten days later, mice received daily intranasal
Ova protein for 3 days. There was no significant difference in
total BALF cell numbers between WT and Rnf128/mice
(Figure S4C). Ova-specific IgG1 was very moderately enhanced
in sera from Rnf128/ mice as compared with controls. Anti-674 Immunity 32, 670–680, May 28, 2010 ª2010 Elsevier Inc.Ova IgG production was the same between WT and mutant
groups. Interestingly, anti-Ova IgM was substantially elevated
in Rnf128/ mice (Figure S4D). When we examined cytokine
expression by splenocytes after ex vivo OVA restimulation,
Rnf128/ cells exhibited enhanced proliferation and all effector
cytokine production by CD4+ T cells (Figure S4E). GRAIL thus
also negatively regulates T cell activation and cytokine expres-
sion in this asthma model.
GRAIL Regulates TCR and CD3 Expression
From above, the deficiency in GRAIL leads to T cell hyperactiva-
tion and their independency on costimulation for activation.
Because other E3 ubiquitin ligases have been implicated in
Figure 5. GRAIL Negatively Regulates TCR-
CD3 Expression
(A and C) Splenic T cells from WT and Rnf128/
OT-II mice were stimulated with OT-II peptide in
the absence (A) or presence of MG-132 (C), and
the expression of TCRb was determined by flow
cytometry. Percentage of CD4+TCRb+ cells is
shown. The results shown are an average of three
independent experiments. (B) Naive CD4+ T cells
from WT or Rnf128/ mice were activated with
plate-bound anti-CD3 for 24 hr. Total cell lysates
from naive or activated CD4+ T cells were probed
with antibodies to TCRb, TCRz, Lck, Zap-70,
PKCq, and LyGDI. b-actin was used as loading
control. Relative immunoblotting signals were
inducted. The results shown are a representative
of at least three independent experiments. (D)
293T cells were transfected with vectors encoding
CD3z, HA-Ub, and either GRAIL or a GRAIL
mutant (GRAIL-m). The lysates were subject to
immunoprecipitation (i.p.) using an anti-CD3z anti-
body. The blot was probed with anti-HA-HRP and
reprobed with anti-CD3z-HRP. (E) CD4+ T cells
from WT and Rnf128/ mice were untreated or
activated with anti-CD3 for 6 hr. MG-132 was
added to all samples for 6 hr. The cell lysates
were i.p. using anti-CD3z antibodies. The blot
was probed with anti-Ub antibodies and reprobed with anti-CD3z-HRP. The results shown are a representative of at least three independent experiments. Rela-
tive immunoblotting signals were calculated as a ratio of ubiquitinated and nonubiquitinated CD3z and shown as average of three experiments.
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meyer and Rao, 2004; Liu et al., 2005), we compared the expres-
sion of these molecules in WT and Rnf128/ T cells. First, we
activated WT and Rnf128/ OT-II T cells with Ova peptide
and WT APCs for different time points and analyzed changes
in the TCRb surface expression by flow cytometry. Ova peptide
stimulation led to TCR downmodulation on WT T cells, whereas
TCRdownmodulation wasmarkedly attenuated in theRnf128/
cells (Figure 5A). After 24 hr of stimulation, WT cells lost approx-
imately 63.4 percent of their TCRb surface expression. In
contrast, Rnf128/ CD4+ T cells retained about 65 percent of
the TCR levels. Thus, GRAIL-deficient T cells are more resistant
to activation-induced TCR downmodulation than WT cells. To
determine whether GRAIL overexpression is sufficient to
enhance TCRb downregulation, TCRb expression was assayed
after TCR engagement in CD4+ T cells retrovirally transduced
to express WT GRAIL or a GRAIL mutant (lacking functional
RING finger domain). In T cells expressing WT GRAIL, we
observedmarkedly enhanced TCRb downregulation in response
to anti-CD3 treatment when compared to T cells transducedwith
an empty vector (Figure S5A). In contrast, overexpression of the
GRAIL mutant delayed TCRb downregulation, suggesting an
important role of GRAIL E3 ligase activity in regulation of cell-
surface TCRb expression.
In addition to surface TCR expression, we also compared the
protein expression of TCR signaling components in naive WT
and Rnf128/ CD4+ T cells or after they were activated for
24 hr with plate-bound anti-CD3. Consistent with increased
TCR surface expression, TCRb and CD3z protein expression
was also enhanced in activated Rnf128/ T cells (Figure 5B).
In contrast, expression of PKCq was not markedly altered and
that of Lck, Zap-70 (both of which are TCR signaling compo-
nents), and LyGDI (a potential substrate of GRAIL) (Su et al.,2006) was reduced, the basis of which is unknown at this stage.
Thus, these results indicate that deficiency of GRAIL results in
selective upregulation of TCR protein expression. To determine
whether GRAIL regulates the expression of TCR through proteo-
some-mediated degradation, OT-II T cells fromWT or Rnf128/
mice were activated with Ova peptide and WT APCs in the
presence of proteosome inhibitor MG-132 or lysosome inhibitor
chloroquine. Addition of MG-132 led to complete inhibition of
TCR downmodulation in both of WT and Rnf128/ T cells
(Figure 5C), whereas chloroquine had no significant effect
(data not shown). Thus, GRAIL may target endocytosed TCR-
CD3 complex via proteosome-mediated degradation.
Because TCRa and -b chains do not have extensive cyto-
plasmic regions, we hypothesize that GRAIL may regulate the
ubiquitinylation of CD3 molecules. CD3z together with WT or
GRAIL mutant were coexpressed in 293T cells along with
HA-tagged ubiquitin. After immunoprecipitation of CD3z and
probing with HA-HRP antibodies, we observed the formation
of high molecular weight ubiquitin conjugates in the present of
WT GRAIL, indicating polyubiquitin chain formation (Figure 5D).
Ubiquitinylation effect was greatly diminished in the presence
of GRAIL mutant. Thus, CD3z is a potential substrate for
GRAIL-mediated ubiquitination. The CD3z intracellular domain
contains eight highly conserved lysine residues, and mutagen-
esis of each revealed that lysine 116 (K116) and possibly K118
might be necessary for GRAIL-mediated ubiquitination of CD3z
(Figure S5B). To investigate further, we analyzed the ubiquitiny-
lation of CD3z in CD4+ T cells from WT and Rnf128/mice. Six
hours after activation in the presence of MG132 to prevent
degradation, T cell lysates were subject to immunoprecipitation
with CD3z antibodies and immunoblotting with Ub antibodies. In
comparison to WT cells, ubiquitination of CD3z in Rnf128/
T cells was substantially reduced (Figure 5E). Thus, GRAILImmunity 32, 670–680, May 28, 2010 ª2010 Elsevier Inc. 675
Figure 6. GRAIL Is Required for Suppres-
sive Function of Regulatory T Cells
(A) Naive WT CD4+T cells were cultured with or
without flow cytometry-sorted WT or Rnf128/
Foxp3-GFP+CD4+ nTreg cells or iTreg in triplicate
wells with plate-bound anti-CD3 and irradiatedWT
APCs. Proliferation was assayed 72 hr after treat-
ment by adding [3H]thymidine to the culture for the
last 8 hr.
(B) mRNA expression of various genes in FACS-
sorted Foxp3-GFP+CD4+ nTreg and iTreg cells
from WT or Rnf128/ KO mice was analyzed by
real-time RT-PCR after restimulation with anti-
CD3 for 4 hr. The graph shows means ± standard
deviation (SD). The results shown are representa-
tive of at least two independent experiments.
(C) mRNA expression of various genes in flow
cytometry-sorted WT Foxp3-GFP+CD4+ iTreg
and Rnf128/ Foxp3-GFP+CD4+ iTreg generated
in the presence or absence of an anti-IL-21 block-
ing antibody was analyzed by real-time RT-PCR
after restimulation with anti-CD3 for 4 hr. The
graph shows means ± standard deviation (SD).
The results shown are a representative of at least
two independent experiments.
(D) Naive WT CD4+T cells were cultured with or
without flow cytometry-sorted WT or Rnf128/
Foxp3-GFP+CD4+ nTreg cells or iTreg in triplicate wells with plate-bound anti-CD3, irradiated WT APCs, and in the presence or absence of blocking antibodies
to IL-21. Proliferation was assayed 72 hr after treatment by adding [3H]thymidine to the culture for the last 8 hr.
(E) Splenic T cells fromWT and Rnf128/were stimulated with anti-CD3 for 24 hr, and the expression of TCRb on gated CD4+Foxp3+ T cells was determined by
flow cytometry. Numbers in dot plot quadrants represent the percentages. The results shown are a representative of at least two independent experiments.
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ubiquitin-dependent proteosome degradation pathway.
Impaired Suppressive Function in Rnf128/ Treg Cells
We also assessed the expression and function of GRAIL in Treg
cell generation and function. Consistent with a recent report
(MacKenzie et al., 2007), we found that GRAIL mRNA expression
was upregulated in naturally occurring as well as TGF-b-induced
Treg cells (data not shown). Because GRAIL is expressed in
TGFb-induced Foxp3-expressing Treg (iTreg) cells, we examined
the role of GRAIL in the generation of this cell subset. Naive CD4+
T cells from WT and Rnf128/ mice were activated with plate-
bound anti-CD3 and anti-CD28 in the presence of exogenous
TGF-b. GRAIL deficiency did not affect the generation of iTreg or
natural Treg (nTreg) cells (Figure S6A).We then tested the function
ofGRAIL inTreg-mediatedsuppressionofproliferation. Incontrast
to cbl-b-deficient T cells (Wohlfert et al., 2004, 2006), naive
Rnf128/CD4+ T cells could be suppressed byWT orRnf128/
nTreg cells (Figure S6B). However, Rnf128/ CD4+CD25+ nTreg
cells exhibited reduced suppression of WT naive CD4+ T cells
when compared with WT Treg cells (Figure S6B).
To avoid possible contamination of effector or memory cells in
the CD25+ T cell population, we crossed Rnf128/ mice to
Foxp3-GFP reporter mice (Fontenot et al., 2005). Similar to the
above results, CD4+ Foxp3-GFP+ T cells from Rnf128/ mice
exhibited reduced suppression activity compared to WT Treg
cells (Figure 6A). Furthermore, using naive T cells from these
animals for induction and purification of iTreg cells, Rnf128/
iTreg also had reduced ability to inhibit the proliferation of naive
CD4+ T cells (Figure 6A). Thus, GRAIL is not required for gener-676 Immunity 32, 670–680, May 28, 2010 ª2010 Elsevier Inc.ation of natural or inducible Treg cells but is required for their
suppression functions.
To further examine why Rnf128/ nTreg and iTreg cells were
impaired in their suppressive function, we compared the expres-
sion of genes betweenWT and Rnf128/ Treg cells after activa-
tion with anti-CD3 for 4 hr by real-time RT-PCR. Rnf128/ Treg
cells did not show any defect in Foxp3, CTLA4, ICOS, IL-10,
PD-1, and TGF-b expression (Figure 6B). In contrast, expression
of Th17 cell-specific genes, such as IL-17, IL-21, RORa, and
ROR-g, were markedly augmented in Rnf128/ Treg cells
compared to WT Treg cells.
Because Rnf128/ iTreg and nTreg cells expressed more
IL-21 than WT cells and IL-21 regulates Th17 cell-related gene
expression in naive and Treg cells (Nurieva et al., 2007a; Yang
et al., 2008), we examined whether this cytokine accounts for
IL-17 expression by Rnf128/ Treg cells and their diminished
suppression activity. Addition of an IL-21 blocking antibody
during the generation of iTreg cells suppressed the expression
of Th17 cell-specific genes, such as those encoding IL-17,
IL-21, and RORg in Rnf128/ cells (Figure 6C). In addition,
blockade of IL-21 signaling in suppression assays using
Rnf128/ nTreg and iTreg cells restored their function to the
levels of WT Treg cells (Figure 6D). These results indicate that
GRAIL is necessary for the function of Treg cells by suppressing
the Th17 cell-related genes.
We further assessedwhether impaired suppressive function of
Rnf128/ Treg cells is associated with their inefficiency in TCR
down-modulation. Anti-CD3 stimulation led to TCR downmodu-
lation on WT Treg cells, whereas TCR downmodulation was
markedly attenuated in the Rnf128/ Treg cells (Figure 6E).
Figure 7. GRAIL Negatively Regulates NFATc1 Expression in Activated Naive and Regulatory T Cells
(A and B) mRNA expression of indicated genes in flow cytometry-sorted Foxp3-GFP+CD4+ nTreg from WT and Rnf128/mice activated with anti-CD3 for 6 hr
in the absence or presence of CsA, anti-IL-2 and anti-IL-21 antibodies were analyzed by real-time RT-PCR. The graph shows means ± standard deviation (SD).
The results shown are a representative of at least two independent experiments.
(C andD)mRNA expression of various genes in naive CD4+ T cells fromWT orRnf128/mice activatedwith anti-CD3 for 24 hr in the absence or presence of CsA,
anti-IL-2, and anti-IL-21 was analyzed by real-time RT-PCR. The graph showsmeans ± standard deviation (SD). The results shown are a representative of at least
two independent experiments.
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mediating downregulation of TCR-CD3 complex.
GRAILDeficiency Causes EnhancedNFATc1Expression
in Naive T and Treg Cells
Our above results indicate that a defect in Rnf128/ Treg cell
activity was functionally associated with increased IL-21 expres-
sion. IL-21 has been shown to be regulated by transcription
factor NFATc1 (Kim et al., 2005). To further address the mecha-
nism whereby GRAIL controls IL-21 expression, Foxp3-GFP+
nTreg cells from WT and Rnf128/ mice were activated with
plate-bound anti-CD3 for 6 hr. Real-time RT-PCR analysis
revealed that whereas WT cells upregulated NFATc1 mRNA
expression, there was a marked enhancement of its expression
in GRAIL-deficient Treg cells after, but not before, activation
(Figure 7A). In contrast, expression of other transcription factors
downstream of TCR signaling such as JunB, c-Jun, c-Fos, and
c-Rel in Rnf128/ Treg cells was similar as that in WT cells
(Figure 7A). Similar toRnf128/ Treg cells, WT Treg cells treated
with MG-132 and Latrunculin B, an endocytosis inhibitor that
prevents TCR downregulation in naive and Treg cells after TCR
engagement (data not shown), also expressed increased
amounts of NFATc1 as well as IL-21, IL-17, and RORg mRNA(Figures S7A and S7B), suggesting that GRAIL-mediated proteo-
some-dependent TCR-CD3 degradation prevents NFATc1
overexpression. NFATc1 autoregulates its own expression by
binding to the P1 promoter, and costimulation greatly enhances
this autoregulatory circuit (Chuvpilo et al., 2002; Nurieva et al.,
2007b). To examine whether NFATc1 autoregulation is required
for expression of IL-17 and IL-21 inRnf128/ Treg cells, WT and
Rnf128/ Treg cells were treated with Cyclosporin (CsA). We
found that blockade of NFAT activities by CsA markedly
decreased the expression of NFATc1 and Th17-specific genes
such as IL-21, IL-17, and RORg (Figure 7B). Interestingly,
blockade of IL-21 did not alter NFATc1 expression, but led to
inhibition of IL-17 and RORg expression (Figure 7B).
Analysis of naive CD4+ T cells from WT and Rnf128/ mice
revealed enhanced NFATc1, IL-2, and IL-21 expression upon
anti-CD3 activation for 24 hr in Rnf128/ cells compared to
WT cells (Figure 7C), whereas JunB, c-Jun, c-Fos, and c-Rel
expression was not affected. Similar to mRNA expression,
NFATc1 total protein as well as translocation to the nucleus
was markedly enhanced in Rnf128/ naive T and Treg cells
upon TcR engagement (Figure S7F). In addition, when we
analyzed the activation of MAP kinase and NF-kB pathways in
WT and Rnf128/ T cells after anti-CD3 treatment, activationImmunity 32, 670–680, May 28, 2010 ª2010 Elsevier Inc. 677
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TCR ligation (Figure S7G). Degradation of IkBawas not substan-
tially changed in Rnf128/ cells compared to WT cells at early
time points after T cell activation (Figure S7H). Thus, enhanced
NFATc1 expression and nuclear translocation byRnf128/ cells
is best associated with enhanced IL-2 and IL-21 production.
Similar toRnf128/ T cells, we also observed enhanced expres-
sion of NFATc1, IL-2, and IL-21 in WT cells treated with MG-132
and Latrunculin B (Figures S7C and S7D). Moreover, we acti-
vated naive T cells fromWT and Rnf128/mice in the presence
of CsA (Figure 7D). Addition of CsA to Rnf128/ T cells and to
WT cells treated with MG-132 inhibited the expression of
NFATc1, as well as IL-2 and IL-21 (Figure 7D; Figure S7E).
Blockade of IL-2 decreased IL-2 and IL-21 mRNA levels, but
did not change NFATc1 expression. In addition, blockade of
IL-21 impaired the expression of IL-21, but not NFATc1
(Figure 7D). Thus, these results indicate that in naive T cells,
GRAIL regulates T cell activation and cytokine production
through negative regulation of NFATc1 expression.
DISCUSSION
The molecular mechanisms underlying immune tolerance have
not been well understood. Using Rnf128/ mice, we found in
the current study that GRAIL is required to properly downregu-
late TCR signaling in recently activated T cells, restrict their cyto-
kine expression, and maintain Treg cell function. Lack of GRAIL
greatly exacerbates autoimmune diseases.
We found that GRAIL mRNA is upregulated during normal
T cell activation even under nontolerant conditions. These obser-
vations suggest that GRAIL function might not be restricted to
T cell anergy, which is supported by an independent study (Krie-
gel et al., 2009). Our analysis on Rnf128/ mice showed that
they are hyper-responsive to immunization with foreign as well
as self antigens. Based on our data, we believe that GRAIL
critically controls the thresholds of T cell activation, and as
a consequence of GRAIL deficiency, immune responses to
exogenous as well as endogenous stimuli are both increased.
On one hand, this may have pathological implication in predis-
posing autoimmune responses. On the other hand, modulation
of GRAIL expression and function may help boost immune
responses to infection and cancer.
E3 ubiquitin ligases, including cbl-b and Itch, negatively regu-
late T cell responses by targeting multiple components of TCR
signaling pathway for degradation.We found that hyperactivation
of Rnf128/ T cells are selectively associated with their ineffi-
ciency in TCR downmodulation. In contrast, expression of other
TCR proximal signaling components, such as PKCq and PLCg1,
were not increased in the absence of GRAIL. We further deter-
mined that TCR downregulation by GRAIL was dependent on
the E3 ligase activity and mediated by proteosome-mediated
degradation. These results suggest that GRAIL, located in the
endosomal compartment, may target endocytosed TCR-CD3
complex via ubiquitination and proteasome-mediated degrada-
tion. In Rnf128/ T cells, early activation of multiple pathways
was not defective. Moreover, endocytosis inhibitor could cause
similar defects in WT T cells seen in the Rnf128/ cells. GRAIL
thus may have more restricted specificity than cbl-b or Itch.
Recently, Lineberry et al. (2008) proposed CD40L as another678 Immunity 32, 670–680, May 28, 2010 ª2010 Elsevier Inc.potential target forGRAIL.However,wedidnotdetectan increase
in CD40L expression inRnf128/ cells in comparison toWT cells
(data not shown). Furthermore, purified Rnf128/ T cells were
hyper-responsive to TCR signaling, independent of APCs, which
is unlikely caused by a defective regulation on CD40L.
A previous study indicates the elevated expression of GRAIL in
Treg cells (MacKenzie et al., 2007). We found that GRAIL was not
necessary for development of Treg cells but was required for
their suppressive function. Unlike cbl-b-deficient T cells (Wohl-
fert et al., 2004, 2006), naive Rnf128/ CD4+ T cells could be
suppressed by WT Treg cells, suggesting that GRAIL deficiency
might not affect TGF-b signaling. In addition, reduced suppres-
sive function was associated with elevated expression of Th17
cell-specific genes, such as those that encode IL-17, IL-21,
and RORg. IL-21was sufficient in upregulating Th17 cell-specific
genes in Treg cells. Inhibition of IL-21 restored suppressive
activity and downregulated Th17 cell gene expression in
Rnf128/ Treg cells. Our studies for the first time indicate a crit-
ical role of GRAIL in control of IL-21 expression in Treg cells.
NFATc1 is strongly induced upon T cell activation and controls
numerous genes that are involved in T cell effector function.
Multiple isoforms of NFATc1 have been recently identified that
are generated by the activity of two different promoters desig-
nated as P1 and P2 (Chuvpilo et al., 2002). The activity of the
P1, but not the P2, promoter is highly induced after T cell activa-
tion and is regulated by costimulation (Nurieva et al., 2007b). The
autoregulation of the P1 promoter by NFAT factors results in
strongly increased NFATc1 protein expression. We found that
Rnf128/ naive and Treg cells after TCR activation expressed
substantially higher amounts of mRNA and protein of NFATc1
compared to WT cells, whereas the activation of other factors
in AP-1 and NFkB pathways were normal. Our data also sug-
gested that sustainedTcRcell-surface expression in the absence
of GRAIL led to selective NFATc1 expression in both naive T cells
and Treg cells, which was supported by our data using an endo-
cytosis inhibitor. In contrast to naiveTcells, increasedexpression
of NFATc1 in Rnf128/ Treg cells was associated with just
enhanced expression of Th17 cell genes. This selectivity may
be controlled at the epigenetic level, which further supports a
close relationship and plasticity between Treg and Th17 cells.
In summary, our results indicate a broad function of GRAIL in
regulation of various aspects of T cell activation and function.
GRAIL, whose expression is enhanced by TCR signaling, by tar-
geting TCR-CD3 for degradation, restricts NFATc1 expression in
recently activated naive and regulatory T cells. This helps the
former to prevent their overactivation and maintain costimula-
tion-dependent effector generation. In addition, GRAIL, through
controlling NFATc1 expression, inhibits IL-21 production and up-
regulation of Th17-specific genes in Treg cells. The immune
regulation by GRAIL in both naive and Treg cells is absolutely
critical as evidenced by the failure of T cell tolerance induction
and greatly increased susceptibility to autoimmune diseases of
Rnf128/ mice.EXPERIMENTAL PROCEDURES
Mice
ARnf128 gene-targeting vector was created by replacing part of exon 4 and all
of exons 5 and 6with the neomycin-resistant gene andwas electroporated into
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blot and PCR analysis, and the appropriately targeted ESCs were injected
C57BL/6 blastocysts. Mice on C57BL/6 3 129 F2 background and C57BL6
F6 were used for our analysis. OT-II TcR transgenic mice were purchased
from Jackson Laboratories. Rnf128/ mice were crossed with OT-II mice to
get GRAIL-deficient OT-II mice. Rnf128/ mice were crossed with Foxp3-
GFP reporter mice. Mice were housed in the SPF animal facility at M.D.
Anderson Cancer Center, and the animal experiments were performed using
protocols approved by Institutional Animal Care and Use Committee.
T Cell Function Analysis
CD4+Foxp3-GFPCD62LhiCD44lo cells were flow cytometry-sorted and
activated under Th1, Th2, Th17, and iTreg cell condition as described (Nurieva
et al., 2007a; Yang et al., 2008). In Figure 6A, naive WT or Rnf128/ CD4+
T cells were cultured with or without WT orRnf128/ Foxp3-GFP+CD4+ nTreg
or iTreg cells in triplicate wells with plate-bound anti-CD3 and irradiated WT
APCs. Proliferation was assayed 72 hr after treatment by adding [3H]thymidine
to the culture for the last 8 hr.
Retroviral Transduction
Naive CD4+CD25CD62LhiCD44lo T cells from OT-II mice were flow cytome-
try-sorted and activated with Ova peptide and irradiated wild-type splenic
APCs. Twenty-four hours after activation, cells were infected by retroviruses
expressing GRAIL, GRAIL mutant, or control empty vector (containing only
IRES-GFP). Four days after infection, GFP+ cells were flow cytometry-sorted
and restimulated with anti-CD3 for 30 min, 1, 2, and 4 hr, after which CD4-
and TCRb-expressing cells were analyzed by flow cytometry.
Quantitative Real-Time PCR
Total RNA was prepared from T cells using TriZol reagent (Invitrogen). cDNA
was synthesized using Superscript reverse transcriptase and oligo(dT) primers
(Invitrogen), and gene expression was examined with a Bio-Rad iCycler
Optical System using iQ SYBR green real-time PCR kit (Bio-Rad Laboratories,
Inc.). The data were normalized to Actb reference. The primers for IL-17,
IL-17F, IL-21, IL-22, IL-10, Foxp3, TGFb, RORg, Junb, NFATcP1, c-Rel,
c-Fos, c-Jun, and Actb were previously described (Evans and Fox, 2007;
Lang et al., 2002; Nurieva et al., 2007a; Rangatia et al., 2003; Rao et al.,
2003; Voice et al., 2004; Xia et al., 2001). The following primer pairs for GRAIL
mRNA were used: forward, TAGCTGTGCTGTGTGCATTG; reverse,
CTTCATGGGGAGAGGCAGTA.
Immunoblot Analysis and Ubiquitination Assay
Nuclear fraction of CD4+ T cells was prepared as described (Nurieva et al.,
2006). Whole T cell lysates were prepared by lysing cells in triton lysis buffer.
The amounts of protein were determined by Bio-Rad protein assay to ensure
equal protein loading for immunoblot analysis with antibodies to TCRb, CD3z,
Lck, Zap-70, PKCq, LyGDI, p38, ERK, NFATc1, b-actin, Lamin B (Santa Cruz
Biotechnology), pp38, and pERK (Cell Signaling).
For ubiquitination assays, cells were lysed in kinase lysis buffer supple-
mented with 1 mM N-ethylmaleimide (NEM). CD3z or CD3z mutants was
immunoprecipitated using CD3z-specific antibody (Santa Cruz Biotech-
nology), and the ubiquitin-conjugated CD3z was detected by IB using anti-
ubiquitin (Santa Cruz Biotechnology).
For the transfection model, 293T cells were transfected in 6-well plates with
retroviral expression vector pIB II containing CD3z-CFP (kindly provided by
Mark Davis, Stanford University), bicistronic retroviral vector pGFP-RV con-
taining Grail or Grail mutant, and pcDNA-HA-ubiquitin. CD3z was isolated by
IP using anti-CD3z, followed by detecting ubiquitinated CD3z by IB using
anti-HA-HRP (Santa Cruz Biotechnology).
Ova Immunization
WT and Rnf128/ KO mice (6–8 weeks old; three per group) were immunized
with Ova protein (1.0 mg/ml) emulsified in CFA (0.5 mg/ml) at the base of the
tail (100 ml each mouse). Seven days after immunization, these mice were
sacrificed and analyzed individually. Spleen cells from Ova-immunized mice
were stimulated in 96-well plates as triplicates with or without OT-II peptide.
IL-2 production was determined 24 hr after T cell activation by ELISA. Prolifer-
ation was assayed 3 days after treatment by adding [3H]-thymidine to theculture for the last 8 hr. Effector cytokines were analyzed 4 days later by ELISA
(PharMingen).
Oral Tolerance Induction
WT and Rnf128/mice were daily administrated intragastrically as previously
described (Zhang et al., 2006). Control mice were given PBS alone. One week
after the last treatment, all mice were immunized subcutaneously with 100 mg
of Ova protein emulsified in CFA. Seven days after immunization, these mice
were sacrificed and spleen cells were stimulated in 96-well plates as triplicates
with or without Ova protein. IL-2 production was determined 24 hr after T cell
activation by ELISA. Proliferation was assayed 3 days after treatment by add-
ing [3H]-thymidine to the culture for the last 8 hr. Effector cytokines were
analyzed 4 days later by ELISA (PharMingen).
Peptide-Induced Tolerance
WT and Rnf128/ OT-II TcR transgenic mice were injected intravenously with
500 mg OVA peptide in PBS or PBS alone on day 0 and day 3. On day 10, the
mice were sacrificed and analyzed individually. Flow cytometry-sorted
Va2+CD44hiD4+ T cells from spleen were restimulated in vitro with plate-bound
anti-CD3. IL-2 production was determined 24 hr after T cell activation by ELISA.
Proliferation was assayed 3 days after treatment by adding [3H]-thymidine to the
culture for the last 8 hr. Effector cytokines were analyzed 4 days later by ELISA
(PharMingen).
EAE Induction
For the induction of EAE, mice were immunized with the MOG peptide emul-
sified in CFA as previously described (Zhang et al., 2004). Signs of EAE were
assigned scores on a scale of 1–4 as follows: 0, none; 1, limp tail or waddling
gait with tail tonicity; 2, wobbly gait; 3, hind limb paralysis; 4, hind limb and
forelimb paralysis.
For transfer, EAE CD4+ T cells (5–10 3 106 cells) from WT and Rnf128/
mice were injected in the tail vein of Rag1 / recipient mice. Twenty-four
hours after T cell transfer, Rag1/ recipients were used for EAE induction
and analysis as described above.
Anti-dsDNA Measurement
dsDNA antibodies in their sera of 2, 18–20, and 26–28 month old mice were
measured by using mouse Anti-dsDNA Ig’s (Total A+G+M) ELISA Kit (Alpha
Diagnostic International, Inc.).
SUPPLEMENTAL INFORMATION
The Supplemental Information includes seven figures and can be found with
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